With Big Pharma Support, Human Gene Editing Could Be Closer Than We Thought

With Big Pharma Support, Human Gene Editing Could Be Closer Than We Thought
Source: Getty Images
Source: Getty Images

Here's how you know CRISPR, the revolutionary gene-editing technology getting all kinds of hype around the web, is poised to go mainstream: Big Pharma's getting in the game.

It was recently announced that a $300 million joint venture between Bayer AG (best known for its aspirin) and bio startup CRISPR Therapeutics will aim to develop drugs for blindness, blood disorders and congenital heart disease. It's a logical next step, especially since scientists at a Los Angeles-based medical institute recently proved they could use CRISPR/Cas9 to treat a type of inheritable blindness in mice.

For a little background, CRISPR/Cas9 gives scientists the ability to directly modify or correct changes in our genome, especially ones that come from disease, by "cutting" the genes with a protein called Cas9, which you might call the scissors. When CRISPR is successful, it means that we can change a busted protein — like one from cancer or HIV — and fully correct the problem.

Source: Getty Images

Because of that, CRISPR's pretty much the prom king of genetic engineering right now. It's been identified as a means of potentially curing genetic diseases, improving international agriculture and even being used as a remote control for switching on and off your DNA. But until now, it was more the focus of small agencies, like CRISPR Therapeutics, and both academic and independent labs.

So far, CRISPR hasn't really ventured into human editing, largely due to ethical and scientific concerns. On the science side, delivery of the Cas9 enzyme to its target — for example, cancer — has been difficult. This is also part of why people are hesitant about looser regulation on GMO foods: If the edit doesn't hit the target, it could change the wrong gene. Or result in a butterfly effect and create some bizarre mutant tomato.

Source: YouTube

What's especially exciting about the venture is that not only are both players focused on helping humans, but a major focus is going to be the delivery system — the weakest link in this whole CRISPR chain. Bayer even has a new department, the LifeScience Center, working toward increasing CRISPR's specificity when it targets DNA sequences. Because accidentally building a mutant is super-bad press for everyone.

But really, spending $300 million to figure out how to make CRISPR more accurate shows that there's a big move toward fixing diseases by directly targeting the disease, instead of trying radiation or drug treatments until something works. With big funding from big pharma, it's not unreasonable to assume that in the next few years, doctors could gain the ability to examine your DNA, identify the problem and be able to edit it out.

We're far from the ability to create Gattaca-esque genetically engineered super-babies, but you have to start somewhere.

How much do you trust the information in this article?

Max Plenke

Max Plenke is a staff writer at Mic, where he covers breaking news, climate science, health and the future. His work has appeared in Esquire, GQ and Wallpaper. Send story tips to max@mic.com.

MORE FROM

Amid new revelations, here’s what we’ve learned about the Russian lawyer who met with Trump Jr.

The picture of Natalia Veselnitskaya is coming into clearer focus.

Republican Senator urges whoever leaked Russia/Sessions phone calls to release whole conversation

Sen. Chuck Grassley wants the person who leaked intelligence about Attorney General Jeff Sessions and Russian ambassador Sergey Kislyak to come forward with more information.

Donald Trump Jr. and Paul Manafort now to testify before Senate committee behind closed doors

Trump Jr. and Manafort have avoided a subpoena and will testify behind closed doors — for now.

Hope Hicks reportedly tried to rein Trump in during explosive ‘Times’ interview. It didn’t work.

The low-profile Trump Whisperer is one of the few in the president's orbit to enjoy job security.

Scaramucci once asked Obama if he’d be softer on Wall Street. It didn’t end well.

The exchange came during a CNBC town hall on the financial crisis, two years into Obama’s presidency.

Trump blasts Hilary Clinton, Comey and ‘Amazon Washington Post’ in tweet storm

He also defended Don Jr. and called Democrats "obstructionists" with "no ideas."

Amid new revelations, here’s what we’ve learned about the Russian lawyer who met with Trump Jr.

The picture of Natalia Veselnitskaya is coming into clearer focus.

Republican Senator urges whoever leaked Russia/Sessions phone calls to release whole conversation

Sen. Chuck Grassley wants the person who leaked intelligence about Attorney General Jeff Sessions and Russian ambassador Sergey Kislyak to come forward with more information.

Donald Trump Jr. and Paul Manafort now to testify before Senate committee behind closed doors

Trump Jr. and Manafort have avoided a subpoena and will testify behind closed doors — for now.

Hope Hicks reportedly tried to rein Trump in during explosive ‘Times’ interview. It didn’t work.

The low-profile Trump Whisperer is one of the few in the president's orbit to enjoy job security.

Scaramucci once asked Obama if he’d be softer on Wall Street. It didn’t end well.

The exchange came during a CNBC town hall on the financial crisis, two years into Obama’s presidency.

Trump blasts Hilary Clinton, Comey and ‘Amazon Washington Post’ in tweet storm

He also defended Don Jr. and called Democrats "obstructionists" with "no ideas."